WallStreetZenWallStreetZen

NASDAQ: BRTX
Biorestorative Therapies Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell BRTX stock?

Based on 1 analyst offering ratings for Biorestorative Therapies Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BRTX stock forecasts and price targets.

BRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-06

1 of 1

Forecast return on equity

Is BRTX forecast to generate an efficient return?

Company
170.49%
Industry
19.2%
Market
168.56%
BRTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BRTX forecast to generate an efficient return on assets?

Company
111.17%
Industry
23.49%
BRTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BRTX earnings per share forecast

What is BRTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$10.10
Avg 2 year Forecast
-$8.26
Avg 3 year Forecast
-$8.36

BRTX revenue forecast

What is BRTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.4M+300.42%
Avg 2 year Forecast
$2.4M+559.18%
Avg 3 year Forecast
$3.2M+790.83%
BRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BRTX revenue growth forecast

How is BRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
107.65%
Industry
30.73%
Market
14.13%
BRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BRTX$1.91N/AN/AHold
XRTX$1.41N/AN/A
ONCO$0.62N/AN/A
ELAB$3.08N/AN/A
SILO$1.47N/AN/A
View Top Biotech Stocks

Biorestorative Therapies Stock Forecast FAQ

Is Biorestorative Therapies Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BRTX) stock is to Hold BRTX stock.

Out of 1 analyst, 0 (0%) are recommending BRTX as a Strong Buy, 0 (0%) are recommending BRTX as a Buy, 1 (100%) are recommending BRTX as a Hold, 0 (0%) are recommending BRTX as a Sell, and 0 (0%) are recommending BRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Biorestorative Therapies stock.

What is BRTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's current Earnings Per Share (EPS) is -$21.40. On average, analysts forecast that BRTX's EPS will be -$10.10 for 2026, with the lowest EPS forecast at -$12.94, and the highest EPS forecast at -$6.93. On average, analysts forecast that BRTX's EPS will be -$8.26 for 2027, with the lowest EPS forecast at -$10.19, and the highest EPS forecast at -$6.09. In 2028, BRTX's EPS is forecast to hit -$8.36 (min: -$9.60, max: -$6.93).

What is BRTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BRTX) forecast ROE is 170.49%, which is considered strong.

What is BRTX's earnings growth forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.3%.

Biorestorative Therapies's earnings in 2026 is -$11,056,581.On average, 4 Wall Street analysts forecast BRTX's earnings for 2026 to be -$12,863,923, with the lowest BRTX earnings forecast at -$16,479,274, and the highest BRTX earnings forecast at -$8,828,182. On average, 4 Wall Street analysts forecast BRTX's earnings for 2027 to be -$10,525,028, with the lowest BRTX earnings forecast at -$12,983,670, and the highest BRTX earnings forecast at -$7,758,100.

In 2028, BRTX is forecast to generate -$10,654,967 in earnings, with the lowest earnings forecast at -$12,234,612 and the highest earnings forecast at -$8,828,182.

What is BRTX's revenue growth forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's forecast annual revenue growth rate of 107.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Biorestorative Therapies's revenue in 2026 is $357,870.On average, 4 Wall Street analysts forecast BRTX's revenue for 2026 to be $1,825,510, with the lowest BRTX revenue forecast at $387,013, and the highest BRTX revenue forecast at $3,344,009. On average, 4 Wall Street analysts forecast BRTX's revenue for 2027 to be $3,005,149, with the lowest BRTX revenue forecast at $1,872,645, and the highest BRTX revenue forecast at $4,179,692.

In 2028, BRTX is forecast to generate $4,061,219 in revenue, with the lowest revenue forecast at $3,121,075 and the highest revenue forecast at $5,016,650.

What is BRTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BRTX) forecast ROA is 111.17%, which is higher than the forecast US Biotechnology industry average of 23.49%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.